Income statement
USD
Annual
| Metric | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32M | -18M | -99K | -178K | -107K |
| EBITDA | -23M | -17M | 6M | -17K | -3M |
| Net Income | -23M | -17M | 5M | -672K | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xcorporeal, Inc. (XCRP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -30.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -30.8%, free cash flow -16.7% with operating margin 0.0% and ROIC -936.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XCRP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XCRP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XCRP Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XCRP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$4.2M
-529.1% YoY
Free Cash Flow
-$225.8K
-428.0% YoY
Revenue Growth
+0.0%
EPS Growth
-30.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32M | -18M | -99K | -178K | -107K |
| EBITDA | -23M | -17M | 6M | -17K | -3M |
| Net Income | -23M | -17M | 5M | -672K | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|
| Cash & Equivalents | 408K | 106K | 197 | 197 | 4K |
| Total Assets | 4M | 17M | 197 | 197 | 4K |
| Total Liabilities | 6M | 2M | 456K | 6M | 5M |
| Shareholder Equity | -2M | 15M | -456K | -6M | -5M |
| Total Debt | 0 | 0 | 17K | 989K | 288K |
| Net Debt | -408K | -106K | 17K | 988K | 284K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
226K
-428.0% YoY
Capital Expenditures
0
Free Cash Flow
226K
-428.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-348.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.